Effect of indomethacin on alteration of ATPase-positive Langerhans cell density and cutaneous sunburn reaction induced by ultraviolet-B radiation.
We have investigated the effect of ultraviolet-B (UVB) irradiation on the density of epidermal ATPase-positive Langerhans cells, and the modulation of this effect by indomethacin (IND). Depilated backs of albino guinea pigs were exposed to varying doses of UVB (10-550 mJ/cm2). Skin biopsies were taken serially. There was an UVB dose-dependent decrease in the density of dendritic epidermal Langerhans cells, as identified by their membrane ATPase activity. This was accompanied by thinning and shortening, or disappearance of dendritic processes. Such changes were followed by a gradual recovery of the cell density to preirradiation level by day 21. Despite the high doses of UVB given, the maximal decrease in the density of ATPase-positive cells was only 58%. Topical application of IND, a prostaglandin-synthetase inhibitor, after irradiation resulted in a decrease of the erythema; however, the decrease in the density of ATPase-positive cells was still observed. In contrast, guinea pigs that received IND topically prior to irradiation showed a decrease erythemal response, but failed to show any decrease in the density of ATPase-positive cells. Administration of IND orally for 3 days prior to UVB exposure did not prevent the decrease in the cell density. The protective effect of topical IND, applied prior to irradiation, may be explained by its in vitro absorbance at both the UVB and UVA ranges. Topical application of IND 20 min prior to exposure to UVB in 2 human subjects resulted in an increase in the minimal erythema dose, giving a sun protection factor of 1.6, which is comparable to that produced by an equimolar concentration of para-aminobenzoic acid solution. The sun-protective property of IND, together with its activity as a prostaglandin synthetase inhibitor, indicate that it potentially could be a useful sunscreen agent. Its clinical safety and efficacy, however, remain to be determined.
D010129:4-Aminobenzoic Acid / Q000494:pharmacology; D000251:Adenosine Triphosphatases / Q000032:analysis*; D000287:Administration, Topical; D000818:Animals; D006168:Guinea Pigs; D007213:Indomethacin / Q000494:pharmacology*; D007801:Langerhans Cells / Q000201:enzymology / Q000528:radiation effects*; D012867:Skin / Q000187:drug effects / Q000528:radiation effects*; D013471:Sunburn / Q000517:prevention & control*; D013473:Sunscreening Agents / Q000494:pharmacology; D014466:Ultraviolet Rays / Q000009:adverse effects*
D013473:Sunscreening Agents; D000251:Adenosine Triphosphatases; D010129:4-Aminobenzoic Acid; D007213:Indomethacin